Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
177Lu-Dotataat plus octreotide bij neuro-endocriene tumoren: NETTER-2
sep 2024 | Maag-darm-leveroncologie